Comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
An inherited disorder affecting adrenal hormone production, causing cortisol deficiency and other hormonal imbalances. Features may include ambiguous genitalia, salt-wasting crises, and growth issues. Treated with lifelong hormone replacement therapy.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
0-null
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
endocrine
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
21-hydroxylase-deficient-congenital-adrenal-hyperplasia-C2936858 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Adrenal hormone imbalance | Cortisol deficiency and other adrenal hormone imbalance may occur. | Not a typical defining feature in the supplied description. | High |
| Genital or salt-related presentation | Ambiguous genitalia or salt-wasting crises may occur. | These features are not established by the supplied description. | High |
| Development and behavior | Growth issues may occur; developmental delay is not the defining feature. | Developmental delay, behavioral concerns, and physical features may occur. | Moderate |
When to favor each condition
Choose 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 when
Suspected adrenal crisis or salt wasting
The supplied CAH description includes salt-wasting crises and cortisol deficiency.
High
Atypical genitalia with endocrine concern
Ambiguous genitalia is a described possible feature of this CAH form.
Moderate
Need for lifelong hormone replacement
The description states treatment with lifelong hormone replacement.
High
Choose 17q11 2 Microduplication Syndrome C3495679 when
Developmental delay with suspected chromosomal change
The syndrome is described as a chromosome 17 segment duplication.
Moderate
Behavioral concerns with congenital features
Behavioral concerns and physical features are described, but not definitive.
Low
Planning early developmental support
The supplied treatment focus is early intervention rather than hormone replacement.
Moderate
How key tests differ
| Test | 21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Adrenal steroid evaluation | May show cortisol deficiency or related hormonal imbalance; exact cutoffs are not supplied. | No characteristic adrenal result is established here. | Abnormal results require clinician interpretation and do not alone prove either diagnosis. |
| Chromosomal microarray | Not the defining test in the supplied description. | May identify a 17q11.2 duplication when clinically indicated. | A copy-number finding needs laboratory and clinical correlation. |
| CYP21A2 or related genetic testing | May support the inherited enzyme-deficiency diagnosis when appropriately ordered. | Does not establish a 17q11.2 microduplication. | Genetic results should be interpreted by a qualified clinician or geneticist. |
Prognosis comparison
21 Hydroxylase Deficient Congenital Adrenal Hyperplasia C2936858
- Outcome
- Chronic endocrine condition; individual outcome is not established here.
- Factors
- Hormone balance, crisis prevention, growth, and treatment adherence may matter.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Chronic congenital condition with variable developmental impact; exact outcome is not established.
- Factors
- Developmental profile, behavioral needs, and access to early support may matter.
Time frame: Both are described as chronic, often recognized early, but onset details are not supplied.
Prognosis should be individualized; no mortality or prevalence figures are provided.
Complications comparison
| Complication | Presentation |
|---|---|
| Acute salt-wasting crisis | Described as a possible serious feature. Not established from the supplied source. Urgent assessment is needed for suspected adrenal crisis. |
| Growth concern | Growth issues are described as possible. Growth effects are not specified in the source. Growth monitoring should be individualized. |
| Developmental or behavioral difficulty | Not a defining complication in the supplied description. Developmental delay and behavioral concerns may occur. Support needs vary and are not predictable from the label alone. |
Patient education highlights
- HighDifferent causes
CAH concerns adrenal hormone production; 17q11.2 microduplication is a chromosomal finding with variable features.
- HighEmergency symptoms
Seek urgent care for suspected salt-wasting or adrenal crisis; do not rely on this comparison for treatment.
- MediumSupport planning
Microduplication care may emphasize early intervention, while CAH care may include lifelong hormone replacement.